A screening threshold is not a diagnosis, and the gap between the two is exactly where the US Army’s new testosterone data lives: a single morning blood draw says a quarter of male soldiers fall below a commonly used clinical cutoff, but that number describes a measurement, not a confirmed medical condition.
Key Points
- A JAMA research letter analyzing 479 male active-duty Army personnel found 25.7% had a morning testosterone reading below 300 ng/dL — roughly 100,691 soldiers Army-wide.
- The estimate drops to 14.7% (about 57,788 soldiers) using a stricter 264 ng/dL threshold, showing how much the “quarter” figure depends on the cutoff chosen.
- Medical guidelines from the American Urological Association and the Endocrine Society require two separate morning measurements plus symptoms before diagnosing low testosterone — this study used one.
- A separate review of over 2.8 million active-duty men found a diagnosed-hypogonadism rate of just 0.43%, underscoring the distance between a screening flag and a recorded illness.
- The findings arrive alongside a Pentagon-mandated annual testosterone screening policy for troops 30 and older, adding institutional weight to how the data gets used.
What the Army’s new numbers actually show
The data come from the Military Health and Nutrition Examination Study, a multisite assessment conducted at five Army installations between August 2024 and January 2026. Researchers drew morning testosterone samples from 479 male active-duty soldiers and published their findings as a research letter in JAMA on October 15, 2026. Using a threshold of less than 300 ng/dL — a level the American Urological Association designates as “a reasonable cut-off in support of” diagnosing low testosterone — the team projected that 25.7% of the Army’s male soldiers, or approximately 100,691 individuals, would register below that line.
The age breakdown matters as much as the headline figure. Younger soldiers fared better: 19.5% of men under 30 fell below 300 ng/dL, compared with 32.8% of men 30 and older. That split tracks a well-established biological reality — testosterone concentrations decline gradually with age in most men — and it also happens to align with the population the Pentagon’s new screening mandate targets first.
Why the number moves when the cutoff moves
Here is the detail that separates a careful reading of this study from a headline skim: the researchers did not report one prevalence figure, they reported two. At the 300 ng/dL threshold, the estimate is 25.7%. At a stricter 264 ng/dL threshold, it falls to 14.7%, or about 57,788 soldiers. Testosterone is a continuous biological measure, not a light switch — a man can sit at 290 ng/dL or at 200 ng/dL, and both register as “below 300,” but clinically they are not equivalent. Choosing where to draw the line changes the headline by nearly half. The researchers also flagged that differences in laboratory assay methods can shift classification for readings that sit close to any cutoff, which is a technical way of saying that borderline cases are genuinely borderline.
Screening is not the same thing as disease
This is the distinction the study’s own authors took pains to state plainly: a single low testosterone measurement is not a diagnosis of hypogonadism. The American Urological Association’s guideline is explicit that the diagnosis of low testosterone “should be made only after two total testosterone measurements are taken on separate occasions,” both conducted in early morning, alongside compatible symptoms or signs. The Endocrine Society’s standard is similarly two-part: unequivocally low, repeat-confirmed concentrations in a man who also shows clinical symptoms of deficiency. Neither body treats a single screening value as sufficient grounds for treatment.
That gap between screening prevalence and diagnosed prevalence is not abstract — it shows up starkly in a separate analysis of Military Health System records covering 2,840,511 active-duty men from 2017 through 2024, which identified only 12,112 diagnosed hypogonadism cases, a rate of 0.43%. Comparing a one-time biochemical flag affecting roughly a quarter of a small sample against a multi-year diagnosis rate affecting under half a percent of the full force illustrates exactly how much clinical confirmation narrows the picture. Neither number is wrong; they are measuring different things.
The policy backdrop that makes this study consequential
The JAMA letter did not appear in a vacuum. Defense Secretary Pete Hegseth ordered mandatory annual testosterone-deficiency screening for active-duty and reserve service members aged 30 and older, a policy framed around military readiness. That mandate was significant enough to draw scrutiny even before this study published — Reuters reported that the Pentagon temporarily rescinded its clinical guidance for the screening program in September 2026 amid questions from physicians about the evidentiary basis for the initiative, and medical professionals had separately raised concerns months earlier about the strength of evidence behind the mandate. The Military Health and Nutrition Examination Study’s new prevalence figures now sit at the center of that debate, since they are the most concrete evidence yet of how many soldiers a screening program of this kind would actually flag.
That institutional context raises its own set of practical questions for the force. Reporting on health implications of the Pentagon’s screening program has noted open questions about whether flagged service members can decline follow-on therapy and how a low reading might affect deployability or duty status — questions the JAMA study does not and cannot answer, because it measured prevalence, not policy consequence.
Following a Department of War memorandum requiring annual testosterone screening for active-duty and reserve military personnel aged ≥30 years, a substantial proportion of male active-duty US Army personnel had a single morning #Testosterone value below commonly used screening… pic.twitter.com/bXBvhPMY8v
— JAMA (@JAMA_current) October 15, 2026
What the evidence supports going forward
Treat the 25.7% figure as what it is: a credible, methodologically disclosed estimate of how often a single morning testosterone reading falls below a commonly used clinical screening threshold among active-duty Army men, drawn from a genuine multisite military health study. Treat it with appropriate caution as a proxy for how many soldiers have hypogonadism, because the study’s own authors, established urology and endocrinology guidelines, and a much larger diagnosed-case database all point the same direction — confirming a diagnosis requires repeat testing and symptom correlation that this screening round did not include. The honest headline is not “a quarter of soldiers are sick.” It is that a quarter of soldiers, on one morning, measured low enough to warrant a second look — which is precisely what a screening program is designed to surface, and precisely why the next phase of research, following these same men through confirmatory testing, will matter more than the number making headlines today.
Sources:
newscientist.com, militarytimes.com, washingtonpost.com, br.headtopics.com, bbc.com, jmvh.org
